Success Loading: Digital App Improves Persistence With Injectable PrEP
People who received injectable cabotegravir for HIV prevention and engaged with a digital health app showed significantly higher rates of persistence at 3 months...
DYAD Study Extension Confirms Long-Term Efficacy of DTG/3TC vs B/F/TAF
Adults with HIV who made the switch to dolutegravir/lamivudine (DTG/3TC) maintained similar virologic efficacy and persistence compared with those who continued bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF),...
Lenacapavir Triplet Regimen is Safe, Tolerable in Patients With HIV-1
The triplet regimen of lenacapavir plus teropavimab and zinlirvimab was safe and well-tolerated in patients being treated for HIV-1, according to early study findings.
Mehri...
Treatment Regimen, Mental Health Influence Persistence After ART Restart
Medication persistence of people with HIV who restart antiretroviral therapy (ART) varies by treatment regimen, with many of these individuals suffering from mental health...